How Much Is a Treatment Center Worth? 2026 Guide

Section 1 · The numbers

2026 treatment center multiples by level of care.

Multiples below reflect the most recent published benchmarks from FOCUS Investment Banking (December 2025 update) and SeaRidge Advisory's behavioral health market guide. Every deal prices on adjusted EBITDA, not revenue and not census, with one exception noted for small mental health practices.

Adjusted EBITDA multiples, U.S. behavioral health, 2026
Level of care	Owner-operated single site	Add-on to a platform	Scaled platform ($5M+ EBITDA)
Detox / residential SUD (RTC)Sub-acute detox, residential addiction treatment	5x-8x+	4x-7x	8x-11x
PHP / IOP programsPartial hospitalization, intensive outpatient	4x-6.5x	4x-7x	8x-11x
Outpatient SUD, mixed servicesOP counseling, MAT-adjacent, hybrid programs	3x-5.5x	4x-7x	8x-11x
Outpatient mental healthTherapy practices, psychiatric and prescriber groups	~1x-2x revenue for solo practices under $1M	4x-7x	10x-14x
ABA / autism servicesFor comparison; the hottest sub-sector	Varies widely	4x-7x	12x-15x

How to read this table. The single biggest driver of your multiple is not your level of care. It is which column you sit in. A residential program earning $1.2M of adjusted EBITDA as an owner-operated single site might trade at 5x-6x, roughly $6M-$7.2M. The private equity platform that buys it may itself trade at 8x-11x. That spread between the add-on price and the platform price is called multiple arbitrage, and it is the entire economic engine behind behavioral health roll-ups. Understanding it is how you avoid selling a premium asset at an add-on price.

Accreditation moves you within the range: CARF or Joint Commission accredited programs consistently achieve 6x-8x EBITDA, while comparable unaccredited programs face a 1x-1.5x multiple discount, per SeaRidge Advisory. Medicaid exposure above roughly 50% of revenue suppresses multiples across every row.

Sources: FOCUS Investment Banking, "Behavioral Health EBITDA Multiples: 2025 Update" (December 2025); Behavioral Health Business Broker / SeaRidge Advisory, "Behavioral Health EBITDA Multiples: Market Guide." For a general-market anchor, BizBuySell's Q1 2026 Insight data shows the typical U.S. small business (all industries) selling for about $350,000 at a 2.7x cash-flow multiple, which is why treatment centers, at 4x-8x and up, are among the more valuable small businesses an owner can hold.

Section 2 · The math

How buyers actually calculate it: adjusted EBITDA.

Nobody buys your tax return. Buyers reconstruct what the business really earns for a new owner, and the gap between reported profit and adjusted EBITDA is where most owners leave money on the table.

Adjusted EBITDA starts with net income, adds back interest, taxes, depreciation, and amortization, then normalizes the expenses that exist because you own the business, not because the business needs them. Above-market owner compensation gets restated to a market-rate replacement salary. One-time legal fees, a website rebuild, a lawsuit settlement, the truck you run through the company, the family member on payroll who has never seen the facility: each one is a documented add-back, and each one gets multiplied.

Here is a worked example modeled on the kind of center I see every month: a licensed residential program reporting $900K in profit that is actually a $1.3M EBITDA business.

Worked example: from reported profit to adjusted EBITDA
Line item	Amount
Reported net income	$900,000
Add back: owner compensation above market replacement	+ $150,000
Add back: one-time legal settlement	+ $85,000
Add back: one-time website rebuild and rebrand	+ $45,000
Add back: personal vehicles and travel	+ $38,000
Add back: family member on payroll, non-working	+ $52,000
Add back: interest and depreciation	+ $30,000
Adjusted EBITDA	$1,300,000

Now watch what that swing does to price. At 5x, $900K of "profit" implies $4.5M. The same business presented as $1.3M of documented adjusted EBITDA implies $6.5M at 5x and $9.1M at 7x. The add-back work in the table above, an afternoon with a good CPA and clean books, is worth between $2M and $4.6M at closing. This is the single highest-leverage hour of the entire sale process, and it is also where undocumented or aggressive add-backs kill deals: 2026 buyers and their lenders verify every line.

If you want a rough sense of where your own numbers land before talking to anyone, our free calculator is a starting point, and the PELORA acquisitions desk runs confidential valuations with no listing and no obligation.

Section 3 · The range within the range

The 7 factors that move your multiple.

Two residential programs with identical EBITDA can sell 3 turns apart. These are the factors buyers actually price in 2026, roughly in order of weight.

Payer mix and network status

In-network commercial contracts mean predictable reimbursement, and buyers pay premiums for them. Programs built on out-of-network billing arbitrage have seen significant multiple compression under payer and regulatory pressure (Scope Research; FOCUS). Heavy Medicaid concentration, above roughly half of revenue, also suppresses pricing.

CARF / Joint Commission accreditation

Accredited programs consistently trade at 6x-8x while comparable unaccredited programs eat a 1x-1.5x discount (SeaRidge Advisory). On $1M of EBITDA that is a seven-figure line item, and accreditation typically takes 12-18 months, so start well before you plan to sell.

Census stability and referral diversity

Buyers model your worst quarter, not your best. Stable census with no single referral source above roughly 20% of admissions reads as durable revenue. One dominant referral relationship reads as a business that walks out the door with a handshake.

Licensure breadth across levels of care

Detox through residential through PHP/IOP under one roof means longer lengths of stay, higher revenue per admission, and a full-continuum story buyers can scale. Single-level programs are add-ons; multi-level programs are platforms in waiting.

Owner dependence

If admissions, payer relationships, and clinical oversight all route through you personally, the buyer is buying a job, not a business. A credentialed clinical director, an admissions team, and documented systems can be worth a full turn of EBITDA on their own.

Clean financials and RCM

In 2026, lenders run forensic diligence on insurance receivables and collections (Behavioral Health Business, Jan 2026). Accrual-basis books, a tight revenue cycle, and receivables that actually collect are now the price of admission, not a bonus.

Compliance and licensing history

State licensing actions, billing audits, and marketing-compliance problems (EKRA, patient brokering) surface in diligence every time. A clean history keeps your multiple; a messy one becomes a price reduction, an escrow holdback, or a dead deal. Our guide to compliant treatment center marketing covers the marketing side of this.

Section 4 · The building

What about the real estate?

If you own your facilities, you own two assets, and they get valued on completely different math. The operating business prices on an EBITDA multiple. The property prices on real-estate fundamentals: comparable sales, cap rates, and, critically, its licensed use. Bundling them into one number almost always undervalues one or both.

Three structures come up again and again:

Sell the operations, keep the property. Lease the facility back to the buyer at market rent. You convert an operating business into passive income secured by a tenant whose license depends on your building.
Sale-leaseback in reverse: sell the real estate to an investor and lease it back before selling the operations, pulling capital out early while keeping the business.
Parallel transactions. Sell business and property at the same time to different buyers, or to the same buyer under separate agreements, so each asset gets priced on its own merits.

This is not theoretical for me. The $14.3M in exits I have been part of included business assets with attached real estate, and the property conversations were as consequential as the EBITDA conversations. A licensed-use facility in a supply-constrained coastal California market, where new treatment beds face years of zoning and neighborhood resistance, carries scarcity value that a generic residential appraisal will completely miss. Get the business valued and the property valued, separately, before you entertain a single offer. The treatment center assets desk handles exactly this combination.

Section 5 · The market

The 2026 reality check: a flight to quality.

The behavioral health M&A market did not collapse. It got selective. Here is the state of play, with sources.

180

Behavioral health deals closed in 2025, up slightly from 176 in 2024. Overall dealmaking has stabilized near 40 transactions per quarter, matching the 2019 baseline.Mertz Taggart, Q4 2025 Behavioral Health M&A Report; FOCUS Investment Banking

Addiction treatment (SUD) deals in all of 2025, including just 7 in Q4, while mental health logged 27 in Q4 alone. SUD is the thin end of the market right now.Mertz Taggart, Q4 2025 Behavioral Health M&A Report

2026

Opened with a "flight to quality." Buyers expect a depressed SUD year with smaller deals, lenders are running forensic diligence on receivables, and premium pricing is concentrating in accredited, in-network, multi-state-ready assets.Behavioral Health Business, "The SUD M&A Cliff" (Jan 13, 2026)

$408B

Projected U.S. mental health and addiction treatment market by 2033, up from $143.62B in 2024, a 12.3% annual growth rate. The demand story underneath the deal slowdown is intact.Grand View Research, U.S. Mental Health and Addiction Treatment Centers Market Report

15,953

SUD facilities in the U.S., plus 14,091 mental health facilities, per the 2024 federal survey. That is the universe of potential sellers, and a large share of it is owned by founders now aging into exits.SAMHSA, 2024 N-SUMHSS Annual Report

5.5 mo

Record average due diligence length in the $5M-$10M enterprise value tier in 2025. Deals are closing, but they are closing slowly and carefully.IBBA & M&A Source, Market Pulse Survey 2025

What this means if your center is healthy: scarcity is working in your favor. With only a few dozen SUD deals clearing per year, buyers with committed capital are competing for a short list of accredited, in-network, clean-books programs, and those assets are still commanding premium multiples while distressed programs trade at discounts or not at all. The worst position in 2026 is being an average asset. The best position is being a clean one in a thin market.

Section 6 · The buyers

What private equity and strategic buyers look for in 2026.

Behavioral health buyers fall into three buckets, and knowing which one you are talking to changes how you should negotiate.

Private equity, platform deal. The fund is buying you as the foundation of a new roll-up. Platforms command the top of the multiple range (8x-11x for addiction treatment, higher in outpatient mental health), and the fund usually wants you to roll equity and stay on for the build. The prize is the "second bite of the apple": your retained stake in a larger platform that later sells at a platform multiple.

Private equity, add-on deal. An existing platform is bolting you onto its footprint. Expect the 4x-7x range, a faster close, and real integration: your brand, systems, and sometimes your team get absorbed. FOCUS notes that buyers prefer geographically contiguous 5-10 location footprints over scattered operations, and platforms with $10M+ EBITDA and 15-20+ locations command the strongest pricing, which is exactly why they can pay you 5x and still create value at 10x.

Strategic buyers. Other operators buying beds, licenses, contracts, or a market. They can pay for synergies a fund cannot, they often close with simpler structures, and they usually want full control with no earnout theater. In a thin SUD market, a motivated strategic who needs your county can outbid a spreadsheet-driven fund.

Diligence in all three cases now covers licensure and compliance history, payer contracts and network status, revenue cycle and receivables aging, referral concentration, clinical staffing and credentialing, and marketing compliance. One more distinction worth understanding: a vetted buyer network is not a listing marketplace. Broadcasting your center on a public listing site tells your staff, your referents, and your competitors that you are for sale, and it attracts tire-kickers. Quiet outreach to qualified buyers, the model we run through PELORA acquisitions and our M&A advisory network, protects the asset you are trying to sell.

Section 7 · The process

How long a sale takes, and the 6 steps.

Across the lower middle market, IBBA's 2025 Market Pulse data shows a median of about 5 months on market and 6-9 months all-in, with diligence in the $5M-$10M tier averaging a record 5.5 months. Treatment centers trend toward the longer end. Plan on 6-12 months and work the steps in order.

Step 01Prepare the financialsMove to accrual-basis books, document every add-back, clean up the receivables, and separate real estate from operations. Months of work, millions of impact. Start 12-24 months out if you can.

Step 02Confidential valuationGet a real number from someone who knows behavioral health comps, not a generic business broker formula. This is where you decide whether to sell now or spend a year fixing the two factors holding your multiple down.

Step 03Quiet buyer outreachTargeted, NDA-gated conversations with vetted PE platforms and strategics. No public listing, no broadcast, no staff panic, no referent rumors.

Step 04Letter of intentPrice, structure, exclusivity, and your post-close role get set here. Everything after the LOI tends to move against the seller, so negotiate the LOI like it is the deal, because it mostly is.

Step 05Due diligenceFinancial, legal, clinical, licensure, payer, and marketing-compliance review. In 2026 this averages a record 5.5 months in the $5M-$10M tier. Survive it by having prepared in Step 1.

Step 06Close and transitionPurchase agreement, license transfers or new licensure applications, payer contract assignments, escrows and earnouts, and your transition period. Then the wire hits.

Section 8 · From the operator's chair

I've sold two of my own centers. Here's what I'd do differently.

Preston Durnford, founder of PELORA Marketing and operator of four treatment centers in Newport Beach and Costa Mesa

SoCal Mental Health, which I co-founded and we grew with over $10M raised, sold in 2024. Fresh Start of California Detox sold in 2025. Between businesses and attached real estate, that is $14.3M in assets moved, and I still operate four centers today: two subacute detoxes and two full-continuum programs across Newport Beach and Costa Mesa. Selling a center you built is nothing like reading about it. Four lessons I paid for:

1. The valuation work should start two years before the sale.

Every add-back I could document cleanly was worth 5x-7x its face value at closing. Every one I could not document was worth zero. If I could send one message back in time, it would be: run the business from day one as if a buyer's forensic accountant is already reading the books.

2. Referral concentration is the silent multiple killer.

Buyers asked harder questions about where clients came from than about anything clinical. Diversified admissions, with real marketing infrastructure behind them instead of two relationships and a prayer, is what separates a 5x conversation from a 7x conversation.

3. The real estate deserves its own negotiation.

The property discussions in my exits moved as many dollars as the EBITDA discussions. Never let a buyer price your building as a rounding error inside the business deal.

4. Confidentiality is worth real money.

The moment a sale rumor reaches staff and referents, census wobbles, and census is the business. Quiet processes protect the very EBITDA you are selling. It is why I will never broadcast-list a treatment center, mine or anyone else's.

More on my background is on the founder page. The operating playbook behind census growth, the thing that makes a center sellable in the first place, is what PELORA's behavioral health marketing practice does all day (here is a case study of that engine in a different healthcare vertical, 2 to 16 patients in 90 days).

Treatment center valuation FAQ

Questions owners actually ask.

What is the average EBITDA multiple for a treatment center in 2026?

Most treatment centers sell for 4x-8x adjusted EBITDA in 2026. Owner-operated residential addiction programs typically land at 5x-8x, PHP/IOP programs at 4x-6.5x, and outpatient programs at 3x-5.5x (SeaRidge Advisory data). Scaled, accredited platforms above $5M EBITDA reach 8x-11x per FOCUS Investment Banking's December 2025 benchmarks. Payer mix, accreditation, and owner dependence decide where you fall in the range.

How do I calculate my treatment center's adjusted EBITDA?

Start with net income, then add back interest, taxes, depreciation, and amortization. Then normalize: add back above-market owner compensation, one-time legal or marketing expenses, personal vehicles, family members on payroll who don't work in the business, and non-recurring costs. Buyers price your center on this adjusted figure, and documented add-backs routinely move a valuation by six or seven figures.

Do out-of-network treatment centers sell for less than in-network centers?

Yes, in most cases. In-network commercial contracts mean predictable reimbursement, so buyers pay premium multiples for them. Programs dependent on out-of-network billing have seen meaningful multiple compression since payers and regulators cracked down on OON arbitrage. Hybrid models with a majority in-network base and some OON upside still price well, while heavily OON-dependent programs get discounted or passed over.

How much does CARF or Joint Commission accreditation add to my valuation?

Accredited programs consistently achieve 6x-8x EBITDA, while comparable unaccredited programs face a 1x-1.5x multiple discount, per SeaRidge Advisory's 2025-26 market data. On a center with $1M of adjusted EBITDA, accreditation can be worth $1M-$1.5M at closing, which makes it one of the highest-ROI moves an owner can make 12-24 months before a sale.

Should I sell my real estate with the treatment center?

Usually not in the same line item. Buyers value the operating business on an EBITDA multiple and the property on real-estate fundamentals, so bundling them typically undervalues one or both. Common structures: sell the operations and lease the property back to the buyer for ongoing income, or sell both in parallel transactions. Owned, licensed-use facilities in supply-constrained markets like coastal California often carry substantial value on their own.

How long does it take to sell a treatment center?

Plan on 6-12 months all-in. Across the broader lower middle market, IBBA's 2025 Market Pulse data shows a median of about 5 months on market and 6-9 months through closing, with diligence in the $5M-$10M tier averaging a record 5.5 months. Treatment centers trend toward the longer end because 2026 buyers and lenders scrutinize insurance receivables, licensure, and compliance history closely.

Is 2026 a good time to sell a treatment center?

It depends on which side of the 'flight to quality' you're on. Deal volume in addiction treatment fell to 33 transactions in 2025 (Mertz Taggart), and 2026 opened selective. That also means less competition for buyer attention if your center is accredited, in-network, and clean on financials. Quality assets are still commanding premium multiples while distressed programs trade at discounts. If your fundamentals are strong, scarcity works in your favor.

What's the difference between selling to a private equity firm and a strategic buyer?

Private equity buyers typically acquire you either as a platform (higher multiple, you may retain equity and stay on) or an add-on to an existing platform (faster close, 4x-7x range, more integration). Strategic buyers, meaning other operators, may pay for synergies and close with less structure, but often want full control. The right answer depends on whether you want a clean exit, a second bite of the apple, or continued involvement, which is exactly what an exit advisor helps you decide before going to market.

Disclaimer. PELORA Marketing (Epic Journey Inc) is a marketing and advisory firm based in Newport Beach, California. We are not a law firm, CPA firm, or licensed broker-dealer, and nothing on this page is legal, tax, investment, or securities advice. Valuation ranges are published market benchmarks that may not reflect your center's specifics. Before selling a treatment center, confirm structure, tax treatment, licensure transfer, and compliance questions with your own healthcare attorney, CPA, and, where required, appropriately licensed transaction professionals.

Rigor

Sources cited on this page.

Every market statistic above traces to a named, published source. Valuation data ages fast; this page is refreshed annually.

FOCUS Investment Banking, "Behavioral Health EBITDA Multiples: 2025 Update" (December 2025): platform, add-on, and sub-sector multiples; platform size and geography preferences.
Behavioral Health Business Broker / SeaRidge Advisory, "Behavioral Health EBITDA Multiples: Market Guide": owner-operated multiples by level of care; accreditation premium and discount; Medicaid exposure effects.
Mertz Taggart, Q4 2025 Behavioral Health M&A Report (via HMP Global / Behavioral Health Executive): 2025 deal counts by sub-sector.
Behavioral Health Business, "The SUD M&A Cliff: A Depressed 2026, Smaller Deals and Emerging Opportunities" (January 13, 2026): 2026 outlook and lender diligence trends.
Scope Research, "Addiction/SUD Treatment Valuation Multiples and M&A Trends 2025": in-network vs out-of-network multiple dynamics.
SAMHSA, 2024 National Substance Use and Mental Health Services Survey (N-SUMHSS) Annual Report (released September 2025): facility counts.
IBBA & M&A Source, Market Pulse Survey reports (Q2-Q4 2025): time on market, time to close, and diligence duration.
Grand View Research, U.S. Mental Health and Addiction Treatment Centers Market Report: market size and growth projections.
BizBuySell, Insight Report (Q1 2026): general small-business sale price and cash-flow multiple benchmarks.

Keep reading, or get your number.

Book a Confidential Valuation Call

How much is a treatment center worth? A 2026 valuation guide from an operator who sold two.